Bristol-Myers and Pfizer Win Approval of New Indication for Eliquis

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pfizer

Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFEannounced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. The drug is now approved for the prevention of blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees, and are at higher risk for deep vein thrombosis, also known as DVT.

“Today’s FDA approval of Eliquis for DVT prophylaxis in patients who have undergone hip or knee replacement is a significant milestone for this important medicine, which is also approved to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrilation,” Bristol-Myers Squibb & Co. and Pfizer Inc. said in a joint press release issued Friday.

The drug is currently marketed in partnership with Pfizer, and is already approved for the prevention of blood clots that can cause strokes in patients with atrial fibrillation, a type of irregular heartbeat that most commonly occurs in the elderly, according to Reuters.

The press release notes that there are currently about 719,000 total knee replacement surgeries and 332,000 hip replacements in the U.S. each year; patients who have had hip or knee replacement surgery are at a greater risk of developing blood clots in the deep veins of the legs (deep vein thrombosis); the clots can travel to the lungs if they break free, a condition known as pulmonary embolism, where they can lead to sudden death.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business